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Summary
Cancer metastases are commonly found in the lymphatic system. Like tumor blood angiogenesis, stimulation of tumor
lymphangiogenesis may require the interplay of several tumor-derived growth factors. Here we report that members of
the PDGF family act as lymphangiogenic factors. In vitro, PDGF-BB stimulated MAP kinase activity and cell motility of
isolated lymphatic endothelial cells. In vivo, PDGF-BB potently induced growth of lymphatic vessels. Expression of PDGF-
BB in murine fibrosarcoma cells induced tumor lymphangiogenesis, leading to enhanced metastasis in lymph nodes. These
data demonstrate that PDGF-BB is an important growth factor contributing to lymphatic metastasis. Thus, blockage of
PDGF-induced lymphangiogenesis may provide a novel approach for prevention and treatment of lymphatic metastasis.
Introduction Tumors stimulate blood and lymphatic vessel growth by
producing angiogenic factors. Although it is known that induc-
The major cause of cancer mortality is metastasis, which relies tion of tumor angiogenesis is a complex process that involves
on de novo formation of blood and lymphatic vessels (Fidler, the interplay of a dozen or more tumor-derived growth factors
2003). While blood vessels support tumor growth by providing (Carmeliet and Jain, 2000; Folkman, 1995; Hanahan and Folk-
nutrients and oxygen, and by removing waste products, the man, 1996), it is poorly understood how tumors induce lymphan-
function of tumor lymphatic vessels remains poorly understood giogenesis, and what its role is in tumor spread (Beasley et al.,
(Dyer et al., 2003). One might expect that sprouting of lymphatic 2002; Williams et al., 2003). Many of the recent research efforts
vessels in the tumor would facilitate tumor immunity by provid- in studying lymphangiogenesis are focused on two members
ing lymph node conduits for antigen-presenting cells. In reality, of the VEGF family, VEGF-C and VEGF-D, which interact with
however, these conduits facilitate the spread of tumor cells to VEGFR-3, a lymphatic endothelial receptor (Alitalo and Carmel-
regional lymph nodes. Indeed, the lymphatics are the dominant iet, 2002). Indeed, both VEGF-C and VEGF-D have been shown
route for tumor cell spread in some of the most common cancer to enhance lymphatic metastasis when expressed at high levels
types, such as breast and colon/rectal cancers (Fidler, 2003). in tumors (Makinen et al., 2001; Skobe et al., 2001; Stacker et
Thus, understanding the molecular mechanisms that control al., 2001).
lymphangiogenesis and its functions will be an important step In addition to members of the VEGF family, tumors with high
in the development of therapeutic agents for prevention and lymphatic metastatic ability also express other growth factors
at high levels (Relf et al., 1997). For example, high levels oftreatment of cancer metastasis.
S I G N I F I C A N C E
Lymphatic metastases are common in solid malignant tumors. However, it remains poorly understood how cancer cells invade the
lymphatic system. Our study provides novel mechanistic insights into tumor lymphatic vessel growth stimulated by tumor cell-derived
lymphangiogenic factors. Here we report that members of the PDGF family, in particular PDGF-BB, which is a growth factor frequently
overexpressed in cancers, are novel potent lymphangiogenic factors. Expression of PDGF-BB in transplanted primary murine sarcomas
leads to regional lymph node metastases in mice. These findings demonstrate that PDGF-BB plays a critical role in stimulating tumor
lymphangiogenesis and lymphatic metastasis. Thus, development of antagonists targeting the PDGF family will be an important
approach in blocking tumor lymphatic vessel growth and metastasis.
CANCER CELL : OCTOBER 2004 · VOL. 6 · COPYRIGHT  2004 CELL PRESS 333
A R T I C L E
PDGF-BB expression have been found in breast cancer tissues
(Coltrera et al., 1995). These distribution studies have raised
the possibility that members of the PDGF family may contribute
to tumor lymphangiogenesis and lymphatic metastasis. The
PDGF family includes at least four structurally related members,
PDGF-AA, -BB, -CC, and -DD (Kazlauskas, 2000), that can form
both homodimers and heterodimers (Heldin and Westermark,
1999). Members of the PDGF family bind to tyrosine kinase
receptors encoded by two genes, PDGFR- and -. PDGF-BB
is the only ligand that can activate both the PDGFR- and -
(Hammacher et al., 1989). Both genetic studies and our own
recent work have demonstrated that members of the PDGF
family are important angiogenic factors (Cao et al., 2003; Lindahl
et al., 1997). Here we have established a murine lymphangiogen-
esis model to assess whether PDGF-BB plays a direct role in
promoting lymphangiogenesis and metastasis. Our data dem-
onstrate that PDGF-BB induces tumor lymphangiogenesis and
metastatic spread to lymph nodes, and show that growth factors
other than VEGFs can play key roles in these processes.
Results
PDGF-BB stimulates lymphatic
vessel growth in vivo
To study the lymphangiogenic properties of PDGF-BB, we used
a mouse corneal lymphangiogenesis model in combination with
confocal microscopy to reveal specific markers that are exclu-
sively expressed on lymphatic endothelial cells. Similar to
FGF-2, PDGF-BB induced a robust angiogenic response in the
mouse cornea (Supplemental Figures S1C–S1F and S1H–S1K).
Within 2 weeks after growth factor implantation, PDGF-BB-
induced corneal neovascularization was almost as potent as
FGF-2-induced angiogenesis in this model (Supplemental Fig-
ures S1B, S1D–S1G, and S1I–S1K). Thus, PDGF-BB is a potent
angiogenic factor in vivo. Under physiological conditions, the
corneal tissue lacks both blood vessels and lymphatic vessels
(Cursiefen et al., 2002). The only lymphatic vessels detected,
using the lymphatic marker LYVE-1 (Banerji et al., 1999; Prevo
et al., 2001), were the preexisting lymphatics in the limbus (Sup-
plemental Figure S3A, LYVE-1). Implantation of the slow-release
polymer without growth factors did not result in the growth of
new lymphatic vessels (Supplemental Figure S3A, PBS). How-
ever, the inclusion of PDGF-BB potently stimulated growth of
new lymphatic vessels sprouting from the existing limbal lym-
phatics (Figures 1C, 1E, and 1G). These newly formed LYVE-1
Figure 1. Stimulation of lymphangiogenesis by PDGF-BBpositive lymphatic vessels were of larger diameter than newly
A–H: Confocal analysis of mouse corneal blood vessels and lymphatic ves-formed blood vessels (Figures 1E and 1G), displayed a different
sels induced by PDGF-BB and FGF-2 at day 25 by immunofluorescent doubledistribution, and generally lacked expression of PECAM-1
labeling for CD31 (red) and LYVE-1 (blue) (A–H). Scale bar  100 m. P 
(CD31). Similar to PDGF-BB, FGF-2 was also able to induce pellet. White arrowheads point to lymphatic vessels and yellow arrowheads
lymphangiogenesis in the corneal model (Figures 1D, 1F, and point to blood vessels.
I and J: Quantification of CD31- (I) and LYVE-1- (J) positive signals from 5–7H). Quantitative analysis showed that PDGF-BB and FGF-2 are
optical fields of different sections.almost equally potent in inducing blood and lymphatic angio-
genesis (Figures 1I and 1J). These data demonstrate that PDGF-
BB is a potent lymphangiogenic factor in vivo.
To further confirm their identity as lymphatic vessels, LYVE- completely overlapping immunostaining patterns were detected
1-positive structures were costained with antibodies against between LYVE-1 and podoplanin (Supplemental Figures S2A–
podoplanin and VEGFR-3, two other specific markers expressed S2C) or VEGFR-3 (Supplemental Figures S2D–S2F). To demon-
on lymphatic vessels (Breiteneder-Geleff et al., 1999; Kaipainen strate that LYVE-1 did not stain blood vessels, corneal sections
et al., 1995). Consistent with previous findings, both VEGFR-3 were double-stained with antibodies against LYVE-1 and CD34
and podoplanin are codistributed on the newly formed lymphatic (a specific marker expressed on blood vessels). Similar to CD31/
LYVE-1 double staining, LYVE-1 positive vessels lacked CD34vessels (Kubo et al., 2002; Schacht et al., 2003). As expected,
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signals (Supplemental Figures S2G–S2L). These data confirm blocked by the anti-VEGFR-3 antibody and the sVEGFR-3-Fc
(Figures 3C–3E). To further assess the blocking activity of thesethe LYVE-1 positive structures in neovascularized cornea as
lymphatics and further validate the specificity of LYVE-1 anti- antagonists, we performed a modified Boyden chamber assay.
Both antagonists effectively blocked the migration of VEGFR3/bodies for lymphatic rather than blood vessel endothelium.
Based on these findings, we chose LYVE-1 as a lymphatic PAE cells, the sVEGFR-3-Fc being more potent than the anti-
VEGFR-3 antibody (Figure 3F).specific marker for the rest of our studies.
Having shown that these antagonists efficiently inhibited the
VEGF-C/-D/VEGFR-3 system in vitro, we further investigatedStimulation of lymphangiogenesis by PDGF-AA
and PDGF-AB their antagonistic effect in vivo. As expected, in the mouse
corneal assay, the anti-VEGFR-3 antibody selectively blockedTo determine whether other members of the PDGF family could
also induce lymphangiogenesis and to compare their lymphan- VEGF-C-induced lymphangiogenesis but had no significant ef-
fects on blood angiogenesis (Figures 3I, 3N, and 3O). Thegiogenic activity, the same amounts of PDGF-AA, -AB, and -BB
were implanted in mouse corneas. Similar to PDGF-BB, PDGF- sVEGFR-3-Fc blocked both VEGF-C-induced blood and lym-
phatic angiogenesis (Figures 3J, 3N, and 3O). By contrast, how-AA and -AB were also able to induce corneal lymphangiogen-
esis. However, the number of lymphatic vessels induced by ever, neither the anti-VEGFR-3 antibody nor the sVEGFR-3-
Fc had any effect on PDGF-BB-induced blood or lymphaticPDGF-AA was significantly less than that induced by PDGF-AB
and -BB (Figures 2D–2I and 2K). PDGF-AB and -BB induced angiogenesis (Figures 3K–3O). Hence these results demonstrate
that PDGF-BB-induced lymphangiogenesis is not mediated viasimilar numbers of lymphatic vessels in this system (Figure 2K).
Since PDGF-AB and -BB, but not PDGF-AA, bind to PDGFR- the VEGF-C/-D/VEGFR-3 pathway.
 (Heldin and Westermark, 1990), these findings suggest that
the PDGFR- plays a critical role in mediating PDGF-induced PDGF-BB is a chemoattractant for primary lymphatic
endothelial cellslymphangiogenesis. Similar to lymphangiogenesis, all three fac-
tors were also able to induce hemangiogenesis (Figures 2A–2C The fact that the VEGF-C/-D/VEGFR-3 neutralizing agents had
no inhibitory effect on PDGF-BB-induced lymphangiogenesisand 2G–2I). However, unlike lymphangiogenesis, the levels of
hemangiogenesis were approximately equal in each case (Fig- suggests that PDGF-BB acts directly on lymphatic endothelial
cells (LECs). To investigate this possibility, human, mouse, andure 2J). Due to its potent lymphangiogenic activity, the remain-
der of our study was focused on PDGF-BB. rat primary LECs were isolated. These LECs expressed lym-
phatic markers such as podoplanin and LYVE-1 (Figures 4A–
4C). PDGF-BB and -AA stimulated migration of mouse andRemodeling of nascent lymphatic vessels
Like blood angiogenesis, the formation of lymphatic vessels human LECs in a concentration-dependent manner (Figures 4D
and 4E). Similarly, VEGF-C, a known chemoattractant for LECs,stimulated by PDGF-BB was readily detectable at day 5 after
implantation, and a maximal response was detectable at day 14 also induced cell motility in a concentration-dependent fashion.
As expected, STI571, a potent PDGFR inhibitor, attenuated bothafter implantation (Supplemental Figures S3B, S3C, and S3G).
During this period, the primitive newly formed lymphatic vessels PDGF-BB- and -AA-induced cell migration (Figures 4D and 4E).
Interestingly, this PDGFR inhibitor also partially inhibited VEGF-underwent remodeling. By day 14, vascular tree-like structures
were found in the PDGF-BB-induced lymphatic vessels, and C-induced cell migration, suggesting that its inhibitory effect
was not only limited to the PDGFR-signaling pathway. Similarsome lymphatic vessels penetrated into the implanted PDGF-
BB pellets. In addition, PDGF-BB-induced corneal blood ves- to mouse and human LECs, PDGF-BB significantly stimulated
the migration of rat LECs (Figures 4F and 4G), but in commonsels were remodeled from the primitive vascular plexuses into
well-organized vasculatures (Supplemental Figures S3B and with PDGF-AA and VEGF-C, it did not regulate the expression
levels of Prox-1 in mouse LECs (Figure 4H). The anti-VEGF-C/S3C). Similar vascular remodeling was also found in FGF-2-
induced lymphatic and blood vessels (Supplemental Figures -D/VEGFR-3 antagonists could not block PDGF-BB-induced
cell migration of human LECs, whereas both neutralizing agentsS3D and S3E). Quantification analysis showed that PDGF-BB
and FGF-2 induced approximately equal numbers of lymphatic blocked VEGF-C-induced migration significantly (Figure 3G).
In light of reports that the Tie2 receptor ligand angiopoietin-2vessels (Supplemental Figures S3G).
(ang-2) can induce lymphangiogenesis (Veikkola and Alitalo,
2002), we considered the possibility that PDGF-BB-inducedBlockage of VEGF-C/-D/VEGFR-3 does not inhibit
PDGF-BB-induced lymphangiogenesis lymphangiogenesis might operate via upregulation of Ang-2.
However, Ang-2 expression levels were not affected by PDGF-One possible explanation for PDGF-BB-stimulated lymphangio-
genesis is that the growth factor induced secondary activation BB stimulation in cells that are known to express PDGF recep-
of the well-characterized VEGF-C/-D/VEGFR-3 system. To ex- tors (Figure 4I) (Furuhashi et al., 2004). These data further sup-
clude this possibility, we investigated the effects of an anti- port the notion that PDGF-BB has a direct effect on LECs.
mouse VEGFR-3 antibody and a soluble VEGFR-3-Fc, both
of which are antagonists of the VEGF-C/-D/VEGFR-3 system. Activation of intracellular signaling pathways
of isolated primary LECsFirstly, we validated the ability of both reagents to block VEGF-
C-induced endothelial cell activity in vitro by using the VEGFR- Stimulation of LEC motility by PDGF-BB suggested that this
factor could activate intracellular signaling components. Indeed,3-overexpressing porcine aortic endothelial (VEGFR-3/PAE) cell
line. In the presence of VEGF-C, these cells underwent dramatic increased levels of phosphorylated Src (P-Src), Erk 1/2 (MAP
kinases, P-Erk1/2), and Akt (protein kinase B) were detected inmorphological changes from regular cell shapes into elongated
spindle-like structures (Figures 3A, 3B, and 3E). This VEGF- rat LECs upon PDGF-BB stimulation. The activation of these
intracellular signaling components was both concentration- andC-induced cell morphological change was almost completely
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Figure 2. Stimulation of lymphangiogenesis by
members of the PDGF family
A–I: Implantation of the same amount of PDGF-
AA, -AB, or -BB in mouse corneas induced both
blood vessel (CD31, red) and lymphatic vessel
(LYVE-1, blue) growth. Scale bar  100 m.
J and K: Quantification of CD31- (J) and LYVE-1-
(K) positive signals from 5–7 optical fields of differ-
ent sections.
time-dependent (Figures 5A and 5B). Similarly, PDGF-AA and Detection of PDGFRs on newly formed
lymphatic vesselsVEGF-C also induced increased levels of P-Src and P-Erk as
compared with those of controls (Figures 5C and 5D). As ex- PDGF-BB exerts its biological functions via activation of two
tyrosine kinase receptors, PDGFR- and - (Heldin and Wes-pected, the protein kinase inhibitor STI571 inhibited the phos-
phorylation levels of these intracellular components, in response termark, 1999). To study the expression of these receptors on
corneal lymphatics, we used a combination of in situ RNA hy-to PDGF-BB and -AA, in a concentration-dependent manner
(Figures 5E and 5F). Interestingly, this PDGFR inhibitor also bridization and antibody staining to colocalize mRNAs coding
for PDGFR- and - with LYVE-1-positive vessels. Lymphaticsignificantly suppressed VEGF-C-induced phosphorylation of
Src and Erk1/2 (Figure 5G), suggesting that this compound has vessels were detected using an anti-LYVE-1-specific antibody
(Figures 6C and 6D, brown color), and PDGF receptor signalsa broad inhibitory effect on several tyrosine kinases. However,
it should be emphasized that STI571 had little effect on VEGF- were determined using probes specific for PDGFR- and -
(Cao et al., 2003). Both PDGFR- and - positive signals wereC-tumor growth in vivo. Although the underlying mechanism of
the differential effects by which STI571 acts in vitro and in vivo detected on PDGF-BB-induced lymphatic vessels (Figures 6C
and 6D, arrows) and on blood vessel endothelial cells (Cao etis not known, it is possible that VEGF-C could utilize other
signaling pathways to promote blood and lymphatic angio- al., 2003). PDGFR- and - were also detected at the protein
level in preimplanted corneal lymphatics as assessed by doublegenesis.
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staining for PDGFR/ and LYVE-1 (Figures 6E–6J, white arrows
point to double positive signals in I and J). Further, to determine
whether LECs in tissues other than cornea also expressed
PDGFRs, we carried out RT-PCR using cDNA prepared from
primary mouse dermal LEC. Again, both PDGFR- and - were
detected in these cells (Figures 6K and 6L). These findings were
further supported by detection of expression of both types of
PDGF receptors on the mouse LEC using Affymetrix gene array
analysis (S.C. and D.G.J., unpublished data).
PDGF-BB promotes primary tumor growth
To determine the role of PDGF-BB in promoting tumor growth,
we transfected a murine fibrosarcoma cell line (T241) with cDNA
coding for human PDGF-BB. Approximately 100 ng/ml PDGF-
BB was secreted into the conditioned medium as quantified
by a sensitive immunodetection assay. Despite a high level of
expression, PDGF-BB did not appear to affect the growth rate
of tumor cells in vitro (Figure 7A), suggesting that these cells
lacked expression of the PDGFRs. However, implantation of
PDGF-BB-expressing tumor cells into C57Bl/6 syngeneic mice
resulted in accelerated tumor growth as measured by both tu-
mor volume and weight (Figures 7B and 7C). Similarly, expres-
sion of VEGF-C, a known lymphangiogenic and blood angio-
genic factor, significantly stimulated tumor growth in vivo
without affecting the growth rate of tumor cells in vitro. The
stimulatory effect of PDGF-BB on primary T241-tumor growth
was statistically significant as compared with control tumors
(p  0.001) (Figures 7B and 7C). Confocal microscopy analysis
using CD31 as a blood vessel marker revealed a significantly
higher density of microvessels present in the PDGF-BB-express-
ing tumors as compared with controls (Figures 7D, 7E, 7G,
and 7H). These tumor vessels appeared as disorganized and
tortuous vascular plexuses with dilated microvessels (Figure
7G). A high density of malformed tumor vessels was also found
in the VEGF-C-expressing tumors (Figure 7F, CD31). In contrast,
relatively well-organized tumor blood vessels were found in wt
and vector-transfected tumor sections (Figures 7D and 7E).
Thus, it appears that both PDGF-BB and VEGF-C are able to
stimulate blood vessel growth in primary tumors.
PDGF-BB induces tumor lymphangiogenesis
Like blood-borne metastasis, lymphatic metastasis may rely on
the outgrowth of host lymphatic vessels into the tumor tissue. To
Figure 3. Inhibition of PDGF-BB- and VEGF-C-induced corneal blood and determine if PDGF-BB could induce tumor lymphangiogenesis,
lymphatic angiogenesis by VEGF-C/-D/VEGFR-3 neutralizing reagents
serial sections of subcutaneous tumors from the margin toward
Blockage of VEGF-C-induced VEGFR3/PAE morphological changes (B–E)
the center were stained with an anti-LYVE-1 antibody. Vector-,and chemotaxis (F) by a rat anti-mouse VEGFR-3 antibody or a sVEGFR-3-
PDGF-BB-, and VEGF-C-transfected tumors expressed GFPFc. Nonstimulated VEGFR3/PAE cells were used as a negative control (A).
Blockage of PDGF-BB and VEGF-C-induced migration of human LEC by a that defined the margins of tumors (Figures 7E–7G). Interest-
rat anti-mouse VEGFR-3 antibody or a sVEGFR-3-Fc (G). Nonstimulated hu- ingly, a high density of lymphatic vessels was found in the
man LEC served as a negative control. Quantification of the percentage PDGF-BB-expressing tumors (Figure 7G). These lymphatic ves-
of morphological changes counted from 10 different optical fields (20)
sels were distributed throughout the entire tumor tissue. Simi-(E). Quantification of the numbers of migrated cells counted from 6 wells
larly, tumor lymphatic vessels were also detected in the entireof each sample (F and G). *p  0.05 and ***p  0.001. VEGF-C alone-
(H), VEGF-C/anti-VEGFR-3 antibody- (I), VEGF-C/sVEGFR-3-Fc- (J), PDGF-BB area of the VEGF-C-expressing tumors (Figure 7F). In contrast,
alone- (K), PDGF-BB/anti-VEGFR-3 antibody- (L), or PDGF-BB/sVEGFR-3-Fc- host lymphatic vessels were located only at the margins of wt
implanted corneal sections (M) were double stained with an anti-CD31
and vector-transfected tumors, and no tumor lymphatics wereantibody (red) and an anti-LYVE-1 antibody (blue) (H–M). Quantification of
found (Figure 7D and 7E). Quantitative analysis showed that theCD31- (N) and LYVE-1- (O) positive signals (n  10 different optical fields).
***p  0.001. Scale bar  100 m. numbers of lymphatic vessels induced by PDGF-BB- and VEGF-
C-expressing tumors were significantly greater than those of
controls (Figure 7I).
To further delineate the role of PDGF-BB in induction of
tumor lymphangiogenesis, we established the mouse corneal
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Figure 4. In vitro effects of PDGF-BB, -AA, and
VEGF-C on isolated primary LECs
A–C: Isolated human (A), mouse (B), and rat (C)
LECs were stained for cell surface podoplanin
(A) and LYVE-1 (B and C) expression. A FITC-con-
jugated secondary antibody was used for signal
detection.
D and E: The chemotactic effects of various con-
centrations of PDGF-AA (blue bar), -BB (red bar),
and VEGF-C (black bar) on mouse (D) and hu-
man (E) LECs were analyzed using a modified
Boyden chamber assay. Migrating cells in the
presence or absence of STI571 were counted
from 12 wells of each sample.
F and G: The number (F) and maximal distance
(G) of migrating rat LECs in the absence and
presence of various concentrations of PDGF-BB.
**p  0.01; ***p  0.001.
H and I: Real-time PCR was used to quantify the
expression levels of prox-1 mRNA in PDGF-BB-,
-AA, or VEGF-C-treated and nontreated mouse
LECs at 12 and 24 hr posttreatment (H), and
Ang-2 mRNA in PDGF-BB-treated and non-
treated mouse melanoma cells (I).
tumor model. Because of the corneal avascularity and lack of positive signals (Supplemental Figures S4H–S4J). Notably, lym-
phatic vessels outside the borders of tumors were relativelylymphatics, tumor growth in the cornea excludes a primary
involvement of any preexisting blood and lymphatic vessels. well-organized with branches (dashes in B–E and G–J). In con-
trast, tumor lymphatic vessels appeared as disorganized vascu-Implantation of tumor tissues into the corneal micropockets
resulted in the growth of tumors expanding from the micropock- lar plexuses generally lacking defined lymphatic vessel struc-
tures (Supplemental Figure S4H). Similar to tumor blood vessels,ets to the limbus (Supplemental Figures S4A and S4F). Corneal
tumor neovascularization became directly visible by gross ex- these premature tumor lymphatic vessels seemed to be leaky
and resulted from fusion of lymphatic capillaries into large lu-amination 2 weeks after implantation. These newly formed tumor
vessels, sprouting from the limbal vessels, infiltrated the entire mens. Triple staining of tumor cells (GFP-positive) and blood
and lymphatic vessels revealed that these premature tumorarea of the tumor tissue. PDGF-BB-expressing tumors were
more potent stimulators of angiogenesis in the cornea than wt lymphatic vessels were distributed throughout the PDGF-BB-
expressing tumors, with nonoverlapping patterns from bloodtumors, and some of the PDGF-BB-induced vessels appeared
as disorganized vascular plexuses (Supplemental Figure S4F). vessels (Supplemental Figure S4J). In contrast to PDGF-BB-
expressing tumors, the distribution of wt lymphatic vessels wasIndeed, immunohistochemical analysis revealed that PDGF-BB-
expressing tumors contained a high vascular density with poten- only limited to the border of the implanted tumor, and no tumor
lymphatics were detected (Supplemental Figures S4C and S4E).tially tortuous and leaky features at the leading edges (Supple-
mental Figure S4G, arrows). In contrast, wt tumors lacked such Most of these lymphatic vessels remained outside the tumor
tissue and appeared as well-structured vessels. Quantificationa disorganized vascularity (Supplemental Figure S4B).
Like blood neovascularization, lymphatic vessels sprouting analysis showed that tumor-produced PDGF-BB significantly
increased the number of blood and lymphatic vessels in thisfrom the existing limbal lymphatics infiltrated the central region
of PDGF-BB-expressing tumors as defined by LYVE-1 and GFP mouse tumor model (Supplemental Figure S4K and S4L). These
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Figure 5. Activation of intracellular signaling
pathways of primary LECs by PDGF-BB, PDGF-AA,
and VEGF-C
Rat LEC were starved in serum-free medium for
12 hr and incubated with various concentrations
of PDGF-BB for 10 min (A), with 100 ng/ml of
PDGF-BB at different time points (B), with 100 ng/
ml of PDGF-AA at different time points (C), or
with 500 ng/ml VEGF-C at different time points
(D) as indicated. Rat LECs were incubated for 10
min with 100 ng/ml of PDGF-BB- (E) and -AA (F),
or 500 ng/ml of VEGF-C (G), in the absence and
presence of various concentrations of STI571 as
indicated. Equal amounts of cell lysates were
analyzed by SDS-PAGE/Western blotting and
probed with specific antibodies against active
forms of Src, Erk1/2 or Akt. The intensity of each
band was quantified.
data demonstrate that PDGF-BB induces tumor growth of lym- Figures 8A–8D). H&E staining revealed the presence of invasive
phatic vessels that consist of relatively malformed, premature, tumor cells in lymph nodes of PDGF-BB- and VEGF-C-tumor
and probably leaky structures. Like blood vessels, such prema- bearing mice. These lymphatic tumor lesions were approxi-
ture lymphatic vessels may contribute to lymphatic metastasis. mately 20-fold larger than the lymph nodes of healthy animals
or animals with wt or vector-transfected tumors as measured by
weight and volume (Figures 8E and 8F). Remarkably, it appearedPDGF-BB promotes lymphatic metastasis
that PDGF-BB-induced lymphatic metastatic lesions were largerStimulation of tumor lymphangiogenesis by PDGF-BB raised
than VEGF-C-induced lymphatic metastases (p  0.05, Figurethe possibility that this factor might promote lymphatic metasta-
8E). In contrast, neither wt nor vector-transfected tumors re-sis. We established a mouse lymphatic metastatic model in
sulted in visible metastases in regional lymph nodes (Figureswhich subcutaneous T241 tumors were grown in the middle
8A and 8D–8F). Histological examination confirmed that GFP-dorsum. After removal of primary tumors, autopsy analysis
positive PDGF-BB or VEGF-C transfected tumor cells wereshowed that a majority of the PDGF-BB tumor-bearing animals
developed metastatic lesions of axillary lymph nodes (n  8, present in axillary lymph nodes, whereas lymph nodes of control
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Blockage of PDGF receptor activation inhibited PDGF-
BB-induced lymphangiogenesis and tumor growth
To determine if inhibitors of the PDGF receptors could affect
PDGF-BB-induced tumoral blood and lymphatic vessel growth,
STI571 (50 mg/kg body weight/day) was used to treat tumor-
bearing mice. This dose was previously reported to sufficiently
block PDGFR activation (Hwang et al., 2003; Uehara et al.,
2003). Administration of STI571 significantly reduced tumor bur-
den as measured by weight and volume after treatment (Supple-
mental Figures S5A and S5B). Interestingly, the number of tumor
lymphatic vessels was lower in the STI571-treated tumors (Sup-
plemental Figure S5C, S5D, and S5H) than in the PBS-treated
tumors. Similarly, the number of blood vessels in the STI571-
treated tumors was also significantly reduced compared to con-
trols (Supplemental Figure S5G). In contrast, STI571 did not
significantly block VEGF-C-induced tumor growth, blood angio-
genesis, or lymphangiogenesis (Supplemental Figures S5A and
S5E–S5H). These data suggest that activation of PDGF recep-
tors is critical for PDGF-BB-induced lymphangiogenesis.
Discussion
Spontaneous lymphatic metastases are the consequence of a
complex metastatic process that includes: (1) dissemination
of malignant cells from a primary tumor to the lymphatics; (2)
transport of tumor cells via the lymphatics to local lymph nodes;
(3) settlement of tumor cells in the lymph nodes; and (4) growth
of metastatic tumors in the lymph nodes. Each of these steps
is critical in facilitating clinical detection of lymphatic metastases
in cancer patients. The question of whether tumor lymphatics
are functional remains controversial (Padera et al., 2002; Skobe
et al., 2001; Stacker et al., 2001). To enter the lymphatic system,
tumor cells must remain in physical contact with lymphatic vessels.
Although the question of how tumor cells enter the lymphatic
vessels remains to be solved, tumor cells may gain access into
the lymphatic system by inducing intratumoral lymphangiogen-
esis or by co-opting preexisting lymphatics in the surrounding
tissue (Beasley et al., 2002; Williams et al., 2003).
A great deal of the recent work in lymphangiogenesis re-
search has been focused on two members of the VEGF family,
VEGF-C and -D, which interact with VEGFR-3. Both VEGF-C
and -D have been found to act on isolated lymphatic endothelialFigure 6. Localization of PDGFRs on newly formed lymphatics
cells in vitro and induce lymphangiogenesis in vivo (Jussila andPBS-implanted corneas (A and B) or PDGF-BB-induced (C and D) lymphatic
Alitalo, 2002). Moreover, overexpression of VEGF-C or -D pro-vessels were stained for LYVE-1 (brown color). The same sections were hy-
bridized with oligonucleotide probes for mouse PDGFR-and  (black dots). motes lymphatic metastasis (Makinen et al., 2001; Skobe et al.,
A–D are bright-field images. Arrowheads indicate LYVE-1 positive signals. 2001; Stacker et al., 2001). However, it seems unlikely that these
Scale bar  10 m. PDGF-BB-implanted corneal sections (day 14) were are the sole factors regulating such processes. For example,
double stained for LYVE-1/PDGFR- (E, G, and I) or LYVE-1/PDGFR- (F, H,
the parallel process of hemangiogenesis involves not onlyand J). Arrows in I and J point to double positive signals. RT-PCR was per-
VEGFs but also many other growth factors such as angiopoie-formed to amplify PDGFR- (K) and - (L) using cDNA prepared from mouse
LECs. Arrows in K and L point to positive signals. tins, FGFs, PDGF, etc. The instability of the tumor cell genome
that may switch on many growth factors during malignant pro-
gression further suggests that multiple factors may be involved
in controlling lymphangiogenesis in tumors (Folkman, 2002).
Among cancer-produced growth factors, expression of mem-
mice lacked detectable GFP-positive tumor cells (Figures 8A– bers of the PDGF family has constantly been reported at high
8C). None of the PDGF-BB, VEGF-C, or control tumor-bearing levels, particularly in breast cancers (Ariad et al., 1991). PDGF-
mice had visible or microscopic pulmonary metastases as de- AA and -BB do not require proteolytic processing for conversion
tected by histological examination (data not shown). In sum- into active forms (Heldin and Westermark, 1999). Previous work
mary, these results demonstrate that PDGF-BB is a potent on elucidating the role of PDGFs in tumor growth has mainly
lymphangiogenic factor that promotes lymphatic metastasis in focused on their direct impact on tumor cells (Uehara et al.,
2003). Recent work performed in our lab, alongside other labs,mice.
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Figure 7. Stimulation of tumor growth, angiogen-
esis, and lymphangiogenesis
A: Growth rates of vector-, PDGF-BB-, VEGF-C-
transduced or wt tumor cells in vitro. T241 tumor
cells were seeded at a density of 1  104 cells/
well in 24-well plates, and triplicates of each
cell line were counted at indicated time points
( SEM).
B: Tumor volumes were measured at indicated
time points and the data are presented as mean
determinants ( SEM).
C: Tumors were weighed at day 13 after implan-
tation and the data are presented as mean de-
terminants ( SEM). ***p  0.001.
D–G: Tumor blood vessels and lymphatic vessels
were double labeled for CD31 (red) and LYVE-1
(blue). Tumor cells in E–G are GFP-positive
(green). Arrows in LYVE-1 panel point to newly
formed lymphatic vessels. T tumor. Scale bar
100 m. Quantification of CD31 (H) and LYVE-1
(I) positive signals (n  7 different optical fields).
**p  0.01; ***p  0.001.
has demonstrated that PDGF-BB and other members of this that PDGF-BB is as potent as VEGF-C in inducing tumor lymph-
angiogenesis and in promoting lymphatic metastasis. Thus, lymph-family are important angiogenic factors (Cao et al., 2002, 2003).
In this paper we show that members of the PDGF family display angiogenesis and lymphatic metastasis are regulated by multiple
factors. Further, our work suggests that PDGF-BB may be adirect potent lymphangiogenic activity. This is based on the
following evidence: (1) both mRNA and proteins of the PDGF survival factor for newly formed lymphatics since PDGF-BB
activates the Akt kinase, which promotes antiapoptotic sig-receptors are localized on newly formed lymphatic vessels; (2)
both PDGFR- and - are detected in isolated primary lymphatic naling.
Deletion of PDGF-B or PDGFR- genes leads to homozy-endothelial cells; (3) PDGF-BB stimulates motility of primary
LEC in vitro; (4) in isolated LEC, PDGF-BB activates intracellular gous lethality at birth. Among the cardiovascular abnormalities,
microvascular hemorrhage and development of edema seemsignaling pathways, such as the MAP kinases Erk1/2 and Akt,
in a way similar to that observed for VEGF-activated signaling to be the major cause of lethality. Although lack of pericyes/
vascular smooth muscle cells (PC/VSMC) in the developing vas-in endothelial cells (Eriksson et al., 2003); and (5) VEGF-C/-D-
VEGFR-3 neutralizing reagents do not block PDGF-BB-induced culatures is the most obvious reason for this hemorrhagic phe-
notype and blood vessel leakage (Leveen et al., 1994; Soriano,lymphangiogenesis in vitro and in vivo. We conclude that PDGF-
BB is a direct lymphangiogenic factor. Our work demonstrates 1994), tissue edema could also be, in part, due to inappropriate
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Figure 8. Promotion of lymphatic metastasis
Implanted subcutaneous T241 tumors were removed and axillary lymph node metastases were visible approximately 3 weeks after removal of primary
tumors. Arrows point to grossly visible lymphatic metastases, and asterisks mark the tumor-free axillary lymph nodes (A–C). Resected lymph nodes and
lymphatic metastases were photographed (D), weighed (E), and the volumes were measured (F). Histological examination of axillary lymph nodes with
H&E staining. LN  lymph node tissues. T  tumor tissues. Dashed lines mark the borders between tumor tissues and lymph node tissues in B and C. ***p 
0.001. Scale bar  25 m.
development of the lymphatic system. In the present study, we gene in mice arrests lymphatic budding from veins, resulting in
embryos lacking lymphatic vasculature (Wigle and Oliver, 1999).have shown that PDGF-BB is a potent lymphangiogenic factor
in the adult animals. Our studies should be validated in the Thus, it is important to study whether Prox-1 regulates expres-
sion levels of PDGF-BB. Two recent independent studies usingfuture by the use of genetic models including PDGFs and their
receptor knockin and knockout mice. It is possible that this Affymetrix gene array analysis show that overexpression of
Prox-1 cDNA in blood vascular and lymphatic endothelial cellsfactor also plays a critical role in the establishment of the lym-
phatic vasculature during embryonic development. The tissue does not seem to induce PDGF-BB expression (Hong et al.,
2002; Petrova et al., 2002). Prox-1 induces differentiation ofedema observed in the PDGF-B/PDGFR- knockout mice could
also be due to a default drainage function of the lymphatic blood vascular endothelial cells toward the lymphatic lineage.
The fact that PDGF-BB does not induce Prox-1 expressionsystem. In physiological conditions, only initial lymphatics lack
mural cells. It still remains unknown, however, if the lymphatic suggests that PDGF-BB-induced lymphatic endothelial cell dif-
ferentiation and assembly of lymphatic vessels are mediatedvessels in the PDGF-B/PDGFR- knockout mice lack PC/
VSMC, which are required to maintain the physiological function via a pathway separated from that activated by Prox-1. These
findings further suggest that although PDGF/PDGFR and VEGF-of the lymphatic system. These interesting issues remain to be
further studied using genetic PDGF-B or PDGFR- knockout C/VEGFR-3 have overlapping developmental functions on lym-
phatic system, the molecular mechanisms by which PDGF/models.
The homeobox gene Prox-1 is an essential early transcrip- PDGFR- and VEGF-C/-D/VEGFR-3 induce lymphangiogenesis
may be regulated by different sets of genes. It is possible thattion factor for lymphatic development. Deletion of the Prox-1
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Mouse corneal neovascularization assaythere is a tissue-specific overlapping role between the VEGF-
The mouse corneal angiogenesis assay was performed as previously de-C/VEGFR-3 and the PDGF/PDGFR signaling pathways in regu-
scribed (Cao et al., 2003) (see Supplemental Experimental Procedures atlation of lymphangiogenesis. This issue should be addressed
http://www.cancercell.org/cgi/content/full/6/4/333/DC1/ for a detailed de-
using tissue-specific VEGF-C/VEGFR-3 or PDGF/PDGFR knockin scription).
and knockout mice. The differential roles of VEGF-C/VEGFR-3
Mouse corneal tumor modeland PDGF/PDGFR signaling in the regulation of lymphangiogen-
Implantation of tumor tissues in the mouse cornea was carried out accordingesis should also be further studied.
to previously described procedures (Muthukkaruppan and Auerbach, 1979)The Prox-1 gene is involved in regulating early events of
(see Supplemental Experimental Procedures for a detailed description).lymphatic development (Hong et al., 2002; Wigle and Oliver,
1999). Perhaps a Prox-1 independent control gene exists that VEGFR3/PAE cell shape changes and motility assay
regulates lymphatic vessel growth, which could be driven by Analysis of VEGFR-3/PAE cell shape changes and motility was carried out
as previously published (Cao et al., 1998) (see Supplemental Experimentalthe PDGF system at later events. It is also possible that the
Procedures for a detailed description).expression of Prox-1 in newly sprouting vessels is maintained
after PDGF-BB treatment, even though the expression level
Lymphatic endothelial cell motility assayis not increased. This basal expression level may already be
Murine LECs were isolated from skin by immunobead selection using an
sufficient for maintaining lymphatic differentiation. Further, pro- antibody targeting mouse LYVE-1. Human LECs were isolated as previously
liferation of LEC may not necessarily lead to elevation of Prox-1 described (Nisato et al., 2004). Expression of podoplanin and LYVE-1 signals
was detected by staining nonpermeablized cells with a rabbit anti-humanexpression. These important issues need to be further explored
podoplanin antibody or a rabbit anti-mouse LYVE-1 antibody. The motilityusing genetic models.
responses of human and murine LECs to PDGF-AA, -BB, or VEGF-C wereThe mouse corneal tumor model is particularly useful to
assayed using a modified Boyden chamber technique previously described
distinguish newly formed lymphatic vessels induced by tumors (Cao et al., 1998). The neutralizing effect of an anti-mouse VEGFR-3 antibody
and the preexisting host vessels, as the cornea lacks both blood or an sVEGFR-3-Fc on PDGF-BB-induced cell migration of human LECs
vessels and lymphatic vessels. Our data clearly demonstrate was analyzed (see Supplemental Experimental Procedures for a detailed
description).that all tumors, including controls and transfectants, were able
Rat LECs were isolated from the thoracic duct as previously describedto induce new lymphatics in this model, whereas only PDGF-
(Mizuno et al., 2003). LEC migration assay was performed according toBB tumors contained tumor lymphatic vessels. The infiltration
previously published procedures (Cao et al., 1998). Briefly, confluent LEC
of lymphatic vessels deeper into the tumor tissue may facilitate cultures grown in 35 mm2 petri dishes were scraped with a razor blade,
lymphatic metastasis by several mechanisms. First, interactions resulting in a cell-free zone of 4 mm2 per dish. The remaining cells were
washed three times and incubated with serum-free endothelial cell basalbetween lymphatic endothelial cells and tumor cells are bilater-
medium-2 in the absence or presence of PDGF-BB (100, 500, or 1000 ng/ally beneficial. While tumor cells produce PDGF-BB and VEGF-C
ml). After 72 hr incubation, cells were fixed with methanol and stained withthat stimulate lymphatic endothelial cell growth and migration,
Giemsa. Two areas of maximal cellular migration/zone were determined.
lymphatic endothelial cells are able to produce tumor growth- The number of cell nuclei and the maximal distance of migration from the
promoting factors. This could potentially stimulate tumor cell starting line were measured (n  8).
growth. Second, the structure of tumor lymphatic vessels ap-
Real-time PCR and reverse transcriptase PCR (RT-PCR)peared to be disorganized, tortuous, and leaky as demonstrated
Two sets of nucleotide primers specific for mouse Ang2 or Prox1 and FAM-in our confocal analysis of LYVE-1 positive vessels. These leaky
labeled probes and primers were used for real-time PCR analysis. As antumoral lymphatics could provide a vulnerable structural basis
internal loading control, 18S ribosomal RNA reagents were used. The follow-
for tumor cell invasion into the lymphatic system. Indeed, the ing amplification cycle program (95C for 10 min, followed by 50 cycles of
high interstitial pressure in the tumor environment would further 95C for 15 s → 60C for 1 min) was used to amplify Prox-1 signals from
force tumor cells into the leaky lymphatics. Finally, lymphatic cDNA prepared from mouse LECs stimulated with or without PDGF-BB, -
AA, or VEGF-C, and to amply Ang-2 signals from cDNA prepared fromendothelial cells may become activated by tumor cells, and they
murine melanoma B16 cells. Relative standard curves were prepared bymay assist tumor cell transport into the lymphatics.
serial dilutions of the positive control. Recalculation was performed as de-In summary, our results show that PDGF-BB is an important
scribed in the manufacturer’s manual for the system.
lymphangiogenic factor that contributes to lymphatic metasta- RT-PCR was performed to amplify PDGFR- and - using cDNA pre-
sis. PDGF-BB is a potent pleiotropic factor that promotes tumor pared from mouse LECs. Primer sequences for PDGFR-: forward; 5	-AACG
GAACCTTCAGCGTGG-3	 and reverse; 5	-GGTACGGTTGTCCTTGAGCC-growth and metastasis through the following three mechanisms:
3	; and for PDGFR-: forward; 5	-GGACGCTGCGGGTGG-3	 and reverse;(1) direct stimulation of tumor cell growth, (2) stimulation of
5	-AACTCGCTGGTCTTGAACGTC-3	. The amplification program consistedangiogenesis, and (3) stimulation of lymphangiogenesis and me-
of 94C for 1 min, 60C for 1 min, and 72C for 1 min for a total of 35 cycles.tastasis. Thus, development of antagonists for PDGF-BB and
other members of the PDGF family may be an important ap- Western blot analysis
proach for control of tumor growth and metastasis. Western blot analyses of lysates from primary rat LECs were performed
according to previously published methods (Eriksson et al., 2003) (see Sup-
Experimental procedures plemental Experimental Procedures for a detailed description).
Animals In situ hybridization
Female and male 6- to 7-week-old C57Bl/6 mice were acclimated and caged Detection of PDGFR- and - in corneal tissues by in situ hybridization was
in groups of six or less. Animals were anaesthetized by an injection of a performed according to recent published procedures using two independent
mixture of dormicum and hypnorm (1:1) before all procedures and sacrificed oligoprobes complementary to PDGFR- (nucleotides 423–470 and 3083–
by a lethal dose of CO2 followed by cervical dislocation. All animal studies 3130) and PDGFR- (946–996 and 2610–2657) (Cao et al., 2003). Briefly,
were reviewed and approved by the animal care and use committee of the slides were exposed on phosphoimager screen overnight to confirm the in
situ hybridization. For immunohistochemistry, the same sections wereNorth Stockholm Animal Board.
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stained with a rabbit anti-mouse LYVE-1 antibody, and positive signals were research grants of Y.C.’s laboratory received from the Swedish Research
Council, The Swedish Heart and Lung Foundation, the Swedish Cancerdeveloped with a streptavidin peroxidase kit (Vectastain ABC kit, Vector
laboratories, Burlingham, CA, USA) combined with a Sigma-Fast-DAB perox- Foundation, the Karolinska Institute Foundation, and the A˚ke Wibergs Foun-
dation. Y.C. is supported by the Swedish Research Council. D.G.J. gratefullyidase substrate (Sigma Aldrich, Steinheim, Germany). To visualize the in situ
hybridization signal, slides were dehydrated, dipped into photo emulsion, acknowledges the financial support of the Medical Research Council, the
Association for International Cancer Research, and Cancer Research UKand exposed for 6 weeks in the dark. Finally, sections were developed,
counterstained with cresyl violet, and analyzed under light and dark field of (C581/A3865). D.G. is supported, through L. Olson, by the Swedish Research
Council and USPH grants. We thank Dr. Elisabeth Buchdunger at Novartisa Zeiss Axiophot microscope.
Pharma for kindly providing us STI71 for this study.
Immunohistochemistry
Frozen corneal sections of 6 m thickness were double-stained for LYVE-1
and each of the PDGFRs according to standard immunohistochemical proce-
dures. A mixture of a rabbit anti-mouse LYVE-1 antibody (Banerji et al., Received: January 28, 2004
1999) and a mouse monoclonal anti-human PDGFR- or - antibody (BD Revised: July 6, 2004
Biosciences Pharmingen, San Diego, CA) was used. A mixture of a goat Accepted: August 19, 2004
anti-rabbit Cy5 (Chemicon International, Temecula, CA) and a rat anti-mouse Published: October 18, 2004
IgG-FITC antibody (Vector Laboratories, Inc., Burlingame, CA) was used for
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